Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AZD4512 monotherapy
AZD4512 · 1 trial · 1 indication
To identify the maximum tolerated dose (MTD) and/or doses of AZD4512 for subsequent evaluation in participants with R/R B-NHL
To assess the safety and tolerability of AZD4512 in participants with R/R B-NHL
To assess the safety and tolerability of AZD4512 in participants with R/R B-NHL
To assess the safety and tolerability of AZD4512 in participants with R/R B-NHL
| Arm | Type | Description |
|---|---|---|
| Module 1: AZD4512 Monotherapy dose escalation + backfill | EXPERIMENTAL | In Mod 1, the efficacy and safety of AZD4512 will be evaluated in R/R B-NHL. Module 1 will consist of both dose escalation and Pharmacodynamic/safety backfills which may be used to support MTD and/or Optimal biological dose (OBD) |
| Name | Type | Description |
|---|---|---|
| AZD4512 | DRUG | AZD4512 is an antibody-drug conjugate targeting cluster of differentiation 22 (CD22) that will be administered via IV infusion |
Key Inclusion Criteria: * Eligible patients must be adults (≥18 years) * Documented histologically confirmed diagnosis of B-cell non-Hodgkin lymphoma (B-NHL) as per World Health Organization (WHO) 2022 classification. In the dose escalation phase, any B-NHL subtype is allowed (excluding some subtyp...
AZD4512 is an investigational small molecule being studied for B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma. It is being evaluated as a monotherapy or in combination with other anticancer agents in clinical trials.
AZD4512 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN.
AZD4512 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials are currently recruiting participants.
AZD4512 is being studied in two recruiting trials: NCT07109219 for B-cell Acute Lymphoblastic Leukemia and NCT07123454 for relapsed/refractory B-cell Non-Hodgkin Lymphoma. Both are Phase 1 studies evaluating AZD4512 as monotherapy or in combination with other anticancer agents.
Yes, AZD4512 monotherapy refers to the same drug, AZD4512, when given alone. The clinical trials also study AZD4512 in combination with other anticancer agents.